AstraZeneca has announced that it has entered into an agreement with Pfizer Inc. to sell the commercialisation and development rights...
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase III RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis
The FDA has approved Noxafil (posaconazole) injection (18 mg/ mL), from Merck, a new formulation of the Fungal Infection treatment...
Avenue Therapeutics, Inc. a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, announced that the FDA was still reviewing its New Drug Application (“NDA”) for IV tramadol and had not provided a decision regarding the NDA.
Top-line results from a Phase IV clinical trial evaluating Mu-Gard Mucoadhesive oral wound rinse, from Access Pharma, shows it was...
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Uptravi (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy.
Recro Pharma, Inc. announced a poster presentation highlighting intravenous (IV) meloxicam's effect on platelet function at the 72nd PostGraduate Assembly...
Pfizer Inc. and Astellas Pharma Inc. announced the Phase IV PLATO study , evaluating the efficacy and safety of continued...
Shire will initiate two Phase IV clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta� (methylphenidate HCl) Extended-Release...
Avenue Therapeutics, Inc. announced that it has received a second Complete Response Letter (“CRL”) from the FDA regarding its New Drug Application (“NDA”) seeking approval for IV tramadol.